About Viage Therapeutics
Viage Therapeutics is a company based in San Francisco (United States) founded in 2018 by Kousaku Ohinata. It operates as a HealthTech. Viage Therapeutics offers products and services including DGX-001, Novel Neuropeptides, and DGX-001-Derived Peptides. Viage Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Ironwood Pharma, among others.
- Headquarter San Francisco, United States
- Founders Kousaku Ohinata
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Viage Therapeutics
Viage Therapeutics offers a comprehensive portfolio of products and services, including DGX-001, Novel Neuropeptides, and DGX-001-Derived Peptides. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
DGX-001 is developed as a gut-brain axis drug.
Novel neuropeptides are researched for cognitive impairment treatment.
DGX-001-derived peptides are explored for psychiatric condition relief.
Funding Insights of Viage Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Viage Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Viage Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Viage Therapeutics Comparisons
Competitors of Viage Therapeutics
Viage Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Ironwood Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Viage Therapeutics
Frequently Asked Questions about Viage Therapeutics
When was Viage Therapeutics founded?
Viage Therapeutics was founded in 2018.
Where is Viage Therapeutics located?
Viage Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Viage Therapeutics?
Titus Plattel is the current CEO of Viage Therapeutics.
What does Viage Therapeutics do?
Viage Therapeutics is engaged in the development of innovative neurotherapeutics targeting the gut-brain axis. The companys lead candidate, DGX-001, is designed to modulate the vagus nerve through gut-specific receptor interactions, aiming to regulate brain activity. Research and clinical trials are conducted to address cognitive impairment, depression, anxiety, and inflammatory diseases. Solutions are explored across neurology and psychiatry sectors with a transdiagnostic study design. A pipeline of novel neuropeptides and second-generation peptides is being developed, emphasizing gut-restricted action to minimize side effects.
Who are the top competitors of Viage Therapeutics?
Viage Therapeutics's top competitors include Jazz Pharmaceuticals, Ironwood Pharma and PTC Therapeutics.
What products or services does Viage Therapeutics offer?
Viage Therapeutics offers DGX-001, Novel Neuropeptides, and DGX-001-Derived Peptides.